redorbit.com
May 22, 2008
Posted on: Thursday, 22 May 2008, 09:01 CDT Schering-Plough has announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infected with hepatitis C virus genotype 1. One study will be in previously...
[read full story]